uniQure N.V.

Equities

QURE

NL0010696654

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:05:47 10/05/2024 BST			5-day change	1st Jan Change
4.86 ^USD	-4.14%		+3.41%	-28.36%

05-08	Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating	MT
05-07	UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

UniQure N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 01, 2023 at 12:37 pm

uniQure N.V. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 2.42 million compared to USD 0.497 million a year ago. Net loss was USD 68.47 million compared to USD 39.06 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 0.84 a year ago.
For the six months, revenue was USD 7.75 million compared to USD 2.29 million a year ago. Net loss was USD 145.7 million compared to USD 85.74 million a year ago. Basic loss per share from continuing operations was USD 3.06 compared to USD 1.84 a year ago.

Latest news about uniQure N.V.

Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating	05-08	MT
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M	05-07	MT
Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director	04-12	CI
UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating	04-02	MT
UniQure N.V.(NasdaqGS:QURE) dropped from S&P Biotechnology Select Industry Index	03-17	CI
Mizuho Securities Adjusts Price Target on uniQure to $7 From $10, Maintains Neutral Rating	03-04	MT
Goldman Sachs Downgrades UniQure to Neutral From Buy, Cuts Price Target to $8 From $63	02-29	MT
UniQure N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
RBC Cuts Price Target on UniQure to $28 From $33, Keeps Outperform Rating, Speculative Risk Qualifier	01-03	MT
Kempen Downgrades UniQure to Neutral From Buy, Cuts Price Target to $18 From $28	12-22	MT
Transcript : UniQure N.V. - Special Call	12-19
Mizuho Downgrades uniQure to Neutral From Buy, Cuts Price Target to $10 From $52	12-19	MT
UniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease	12-19	CI
UniQure Says US FDA Clears Investigational New Drug Application for Fabry Disease Candidate	11-29	MT
UniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease	11-29	CI
Worldwide Healthcare Trust net asset value slips in volatile markets	11-23	AN
Goldman Sachs Increases Price Target on uniQure to $63 From $56, Maintains Buy Rating	11-08	MT
RBC Cuts Price Target on uniQure to $33 From $37, Keeps Outperform, Speculative Risk	11-08	MT
UniQure N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Earnings Flash (QURE) UNIQURE Posts Q3 Revenue $1.4M	11-07	MT
UniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy Annual Meeting	24/10/23	CI
UniQure N.V. Announces Chief Scientific Officer Changes	05/10/23	CI
UniQure to Cut 114 Jobs as Part of Restructuring Plan to Lower Expenses	05/10/23	MT
UniQure to lay off about 20% of workforce	05/10/23	RE

Chart uniQure N.V.

Duration

Period

More charts

Company Profile

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.

Sector

Biotechnology & Medical Research

Calendar

13/05/2024 - RBC Capital Markets Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Ratings for uniQure N.V.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.705 EUR

Average target price

19.31 EUR

Spread / Average Target

+310.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
UNIQURE N.V.	-28.36%	246M
VERTEX PHARMACEUTICALS INCORPORATED	+3.81%	108B
REGENERON PHARMACEUTICALS, INC.	+11.14%	104B
ARGENX SE	+1.28%	22.33B
BIONTECH SE	-12.80%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-38.36%	17.74B
BEIGENE, LTD.	-10.63%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+3.80%	14.05B
SAREPTA THERAPEUTICS, INC.	+37.32%	12.51B

Bio Therapeutic Drugs